Research Article
Clinical Features and Resistance to Entecavir Monotherapy of Patients with Hepatitis B
Table 3
Factors contributing to ETV monotherapy resistance (multivariate analysis).
| | Characteristics | Univariate OR (95% CI) | value | Multivariate adjusted OR (95% CI) | value |
| | Age at the beginning (＜65 years) | 4.8 (1.1–21.9) | | — | — | | Gender (male) | 4.1 (1.2–14.1) | | — | — | | Baseline AST (≧2 × ULN) | 3.0 (0.9–8.3) | | — | — | | Baseline ALT (≧3 × ULN) | 5.4 (1.7–17.9) | | 3.3 (0.9–13.6) | | | Prior exposure to NA therapies (yes) | 1.1 (0.3–4.3) | | — | — | | Baseline HBeAg (positive) | 3.4 (1.1–9.4) | | — | — | | Baseline HBV DNA (≧5 LogC/mL) | 4.4 (1.3–15.3) | | — | — | | Baseline HBcrAg (≧5 LogU/mL) | 7.3 (1.8–34.5) | | 4.7 (1.0–34.0) | | | Genotype C (yes) | 1.1 (0.3–4.1) | | — | — | | Fibrosis stage (≦F2) | 5.2 (0.8–60.9) | | — | — |
|
|
